Cutting- Edge Cancer Tx Accelerated Target ID by 75% using ML & Curated Biomolecular Data

CASE STUDY

Cutting- Edge Cancer Tx Accelerated Target ID by 75% using ML & Curated Biomolecular Data

Key Highlights

The company aimed to find targets for differentiation therapy for cancers including AML.
‍
Data retrieval, harmonization and ML model development are time-consuming.
‍
To help the company circumvent the time factor, Elucidata curated an omics data atlas and developed custom pipelines.
‍
The company was able to identify two targets in 2-3 months compared to the 1-2 years that it generally takes.

All Case Studies

Oncology Company Achieves ~80% Acceleration in Gene Target ID/ Validation

Pharma-AI Collaboration Drives ~$3M Cost Reduction by Using Highly Curated Public Data

Leading Oncology Company Uses Elucidata’s Drug OmixAtlas to Drive Drug Discovery

Polly PeakML Accelerates Biological Insight Derivation from Untargeted Metabolomics Analysis

Cutting- Edge Cancer Tx Accelerated Target ID by 75% using ML & Curated Biomolecular Data

Cloud Processing of Metabolomics Data

Accelerate Cell-Type Annotation of scRNA-seq Data

Predicting Survivability of Patients with Liver Hepatocellular Carcinoma

Integrated Metabolomics and Transcriptomics Profiling

Network Integration of Parallel Metabolic and Transcriptional Data Reveals Metabolic Modules that Regulate Macrophage Polarization

Why Polly CRISPR Screening is Better than MAGeCK VISPR

Other Resources

Webinars Whitepapers Blogs Documentation Datasets Solution Briefs